Nasdaq:US$32.17 (+0.00) | HKEX:HK$50.40 (+0.75) | AIM:£4.71 (+0.02)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 22 Nov 2007

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

1 items
a071122